How big is the development space for biopharmaceuticals? If you want to give a specific and accurate value, the author can't give it at present, but from the biopharmaceutical companies' last year's financial report and the future situation of some experts and industry analysts, even if the value cannot be determined. But I can also know a little from it.
Let's first take a look at the performance of biopharmaceutical companies in 2017. The total sales of Johnson & Johnson drugs exceeded the $36 billion mark. Among them, the tumor combination was indispensable, and multiple myeloma drugs and blood cancer drugs have also proved to be crucial for the growth of the combined business. Lilly's performance is stable, although it has investments in the field of neuroscience and oncology, but it is still focused on diabetes. Lilly also hopes that the new drug will help it offset the sluggishness of insulin.
Merck's performance in the past year is not bad, its products help Merck lead the cancer immunotherapy market, helping its first-line lung cancer to form a strong competitive advantage, stimulating rapid sales growth. In addition, the author was informed that Roche is preparing to expand from Europe to the United States, and new drugs are the key to the plan.
From this point of view, the performance of leading biopharmaceutical companies in 2017 has its own merits, and the competition in 2018 has gradually begun. In order to make a comprehensive plan, biopharmaceutical companies need to understand the development trend of the industry this year. So, for biopharmaceutical companies, what trends are not to be missed in 2018?
1.2018 is expected to become the global biopharmaceutical merger and acquisition year.
Specifically, bio-pharmaceutical M&A transactions will show an upward trend in 2018, although it is likely that the transaction volume in 2017 will be too low, but any increase will increase the M&A performance of the bio-pharmaceutical industry in 2018. With the encouragement of social capital to participate in the reform of the medical system and the concept of “healthy China†to drive domestic mergers and acquisitions, the speed of overseas mergers and acquisitions by Chinese pharmaceutical companies is also accelerating. It is also predicted that overseas mergers and acquisitions will be included in the development strategy of more Chinese pharmaceutical companies.
2. Bioprocess trends are affecting the technical requirements and purchasing patterns of end users of the process.
The biopharmaceutical industry is singing all the way, but the related processes cannot fully meet the needs of the industry. With the impact of bioprocess trends on the technical requirements and purchase patterns of end users, and the slowdown in process innovation, biopharmaceutical companies are under tremendous pressure. In order to face the current situation and make practical results, some powerful leading pharmaceutical companies have begun to establish a customer-centered collaborative research and development of new product methods. Small and medium-sized enterprises can also initiate innovation and change the status quo through cooperation.
3. Many large pharmaceutical companies are eyeing the Asian market.
Asia has a large population and many consumer needs, especially China. At present, China has become the second largest consumer market for medicines and accounts for a quarter of the world's medical market. Many large pharmaceutical companies, such as Thermo Fisher, Merck and Johnson & Johnson, also attach importance to the Chinese market. In order to grasp the Chinese market, major biopharmaceutical companies are striving to maintain R&D investment and increase product productivity through innovation.
4. Global competition is always a trend and will continue to be followed in 2018.
Where there is a market, there is competition. For the fat of biopharmaceuticals, the "battlefield" is not limited to one place, but global. According to the survey, an important trend in the biopharmaceutical field this year is to increase production efficiency to meet growing demand and reduce costs to improve the overall quality of products.
Ems Sculpting Machine,Ems Muscle Stimulator,EMS Machine
Xi'an Double H Health Technology Co., Ltd , https://www.dhextract.com